In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Added contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase C, https://danielk665xis8.blogolenta.com/profile